Stem Cell Agency Invests Almost $20 Million in Clinical Trial for Deadly Brain … – Newswise (press release)
|
Stem Cell Agency Invests Almost $20 Million in Clinical Trial for Deadly Brain …
Newswise (press release) Newswise — San Francisco, CA – Glioblastoma is the most common and the most aggressive form of brain tumor, so funding an equally aggressive approach to treating it was a no-brainer for CIRM, California's stem cell agency. The agency's governing … ImmunoCellular Therapeutics (IMUC) Announces $19.9M Award from CIRM to Fund … ImmunoCellular secures grant for clinical trial of glioblastoma |
